AbbVie (ABBV) lifted its full year 2026 revenue guidance to about US$67.6b, adding US$300m to its outlook, while also issuing third quarter revenue guidance and reporting detailed second quarter results.

Despite AbbVie lifting its 2026 revenue outlook and reporting higher second quarter sales and net income, the stock has recently cooled, with the 7 day share price return down 6.88% and the 30 day share price return down 6.12%. That comes after a stronger run, including a 90 day share price return of 19.54% and a 1 year total shareholder return of 27.27%. This points to longer term momentum even as investors reassess near term risks and growth expectations.

If AbbVie’s guidance change has you thinking about where growth could come from next in healthcare, it may be worth scanning other opportunities in 41 healthcare AI stocks

AbbVie has raised its 2026 revenue outlook while the stock has cooled after a strong 1 year run. Is most of the share price progress already behind you, or does the current valuation still leave meaningful upside on the table?

Most Popular Narrative: 8.2% Undervalued

AbbVie’s most followed narrative points to a fair value of $266.89 per share compared with the last close at $245.10. This frames the recent pullback as pricing in a discount that this narrative attempts to explain.

AbbVie's diversified and expanding late-stage and early-stage pipeline, coupled with consistent business development activity (e.g., Capstan in vivo CAR-T, Gubra amylin analog for obesity, next-gen siRNA platforms), positions the company to capitalize on the increasing adoption of biologics and specialty pharmaceuticals, which can reinforce premium pricing and protect net margins.

Curious how that pipeline story turns into a higher fair value for AbbVie? This narrative leans heavily on stronger margins and faster earnings growth than current profits suggest. It also assumes the market will still give AbbVie a premium earnings multiple years from now.

Result: Fair Value of $266.89 (UNDERVALUED)

However, AbbVie’s story could change quickly if key products face faster competitive pressure or if new acquisitions like Apogee fail to deliver as expected.

Another View: AbbVie On Traditional Earnings Metrics

The first narrative leans on future cash flows and long range forecasts to argue AbbVie is 8.2% undervalued. On a simple P/E basis, the picture is very different. AbbVie trades on 69.1x earnings, compared with 22.2x for peers, 17x for the US biotechs industry, and a fair ratio of 39.2x. That gap points to meaningful valuation risk if sentiment cools or earnings do not scale as expected. Which story do you trust more when deciding how much risk to take on?

Next Steps

The mix of optimism and caution around AbbVie is clear, so it makes sense to review the underlying data yourself and move quickly to shape your own view. A good place to start is by weighing the company's 3 key rewards and 4 important warning signs.

Looking for more investment ideas beyond AbbVie?

If you stop with AbbVie, you could miss other opportunities that fit your goals. Use the Simply Wall St screener to compare fresh ideas side by side.

• Target long term compounding potential by scanning companies that look attractively priced and financially resilient through the 53 high quality undervalued stocks
• Prioritise income by focusing on companies that currently offer strong yields and robust payout profiles using the 7 dividend fortresses
• Protect your capital by concentrating on businesses that score well on resilience and risk using the 82 resilient stocks with low risk scores

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.